Onyx Pharmaceuticals Inc. (ONXX) gapped open sharply lower Thursday and has continued to lose ground in early trade. The stock is now down 11.23 at $113.00. Onyx Pharmaceuticals has fallen to a month and a half low and has dropped …
Today's upside move in Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) (+8%) is being attributed to renewed takeover buzz. The stock is trading 2x normal and the call are very active on the option exchange.
Onyx Pharmaceuticals (ONXX) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the …
Among biotech and emerging pharmaceutical companies, Gilead Sciences (NASDAQ: GILD) and Onyx Pharmaceuticals (NASDAQ: ONXX ... Idec stock has outperformed that of larger competitor Pfizer (NYSE: PFE), as well as the broader …
Onyx Pharmaceuticals (ONXX): The company, subject of recent takeover talk ... Face jackets is lowered to Neutral from Outperform at Credit Suisse. (See also: New Stock Coverage: Tremor Video Inc All Set to Shake Things Up and Stock
Welcome to the Stock ... Amgen topped the Street view in terms of earnings projections but is slightly below the consensus sales forecast. I’m not overly concerned about this. Now that Amgen has acquired cancer drug specialist …
Highlighted stocks include: Myriad Genetics (Nasdaq: MYGN), Onyx Pharmaceuticals Inc. (Nasdaq: ONXX), AMAG …
Fueling the fire was the proposed acquisition of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN) for a 38% premium. Onyx’s management rejected the proposal and put itself up for sale. The stock
Upon breaching this level, it may go down to $94.54 level. Onyx traded 942,150 shares during yesterday’s session, and the stock oscillated in the range of $97.82 and $101.43. ONXX has appreciated 123.04 percent in the past 52 weeks. The …
Some analysts feel that Celgene's stock is undervalued. Trading at $61.29 at close Thursday ... potentially seeking US approval within the next few years. Onyx Pharmaceuticals (ONXX) Onyx recently asked the FDA to approve its drug …